A phase I study of pharmacokinetics of trastuzumab emtansine in Chinese patients with locally advanced inoperable or metastatic human epidermal growth factor receptor 2-positive breast cancer who have received prior trastuzumab-based therapy

BACKGROUND: Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that retains the antitumor effects of trastuzumab while also delivering the cytotoxic antimicrotubule agent, DM1, directly to tumor cells that overexpress human epidermal growth factor receptor 2. The pharmacokinetic (PK) profil...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Dongmei, Shen, Weina, Zhang, Jian, Cao, Junning, Li, Wenhua, Lam, Lisa H., Wu, Fan, Wang, Bei, Li, Zao, Sun, Guofang, Hu, Xichun, Chen, Shang-Chiung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
5750
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598804/
https://www.ncbi.nlm.nih.gov/pubmed/33126339
http://dx.doi.org/10.1097/MD.0000000000022886

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7598804/
https://www.ncbi.nlm.nih.gov/pubmed/33126339
http://dx.doi.org/10.1097/MD.0000000000022886

Ejemplares similares